{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:55:03Z","timestamp":1788288903219,"version":"build-2803163510"},"reference-count":179,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Tissue Res"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00441-026-04055-8","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T02:45:34Z","timestamp":1772505934000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Brain peptides in Alzheimer\u2019s disease - pathophysiology and therapeutic advances"],"prefix":"10.1007","volume":"403","author":[{"given":"Sonu","family":"Pahal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arushi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monu","family":"Kaushik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishvender","family":"Pahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geethika","family":"Atluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3079-7239","authenticated-orcid":false,"given":"Amit","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"4055_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1006\/frne.1994.1013","volume":"15","author":"G Aguilera","year":"1994","unstructured":"Aguilera G (1994) Regulation of pituitary ACTH secretion during chronic stress. Front Neuroendocrinol 15:321\u2013350. https:\/\/doi.org\/10.1006\/frne.1994.1013","journal-title":"Front Neuroendocrinol"},{"key":"4055_CR2","unstructured":"Aguzzoli CS, Anstey KJ, Atri A et al (2024) World Alzheimer Report 2024: Global changes in attitudes to dementia. Contributors: Survey translators. Alzheimer\u2019s Disease International, pp. 1\u2013176"},{"key":"4055_CR3","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/j.1532-5415.1989.tb02264.x","volume":"37","author":"SG Albert","year":"1989","unstructured":"Albert SG, Nakra BRS, Grossberg GT, Caminal ER (1989) Vasopressin response to dehydration in Alzheimer\u2019s disease. J Am Geriatr Soc 37:843\u2013847. https:\/\/doi.org\/10.1111\/j.1532-5415.1989.tb02264.x","journal-title":"J Am Geriatr Soc"},{"key":"4055_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102270","author":"VN Almeida","year":"2024","unstructured":"Almeida VN (2024) Somatostatin and the pathophysiology of Alzheimer\u2019s disease. Ageing Res Rev. https:\/\/doi.org\/10.1016\/j.arr.2024.102270","journal-title":"Ageing Res Rev"},{"key":"4055_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177510","author":"SM Alqahtani","year":"2025","unstructured":"Alqahtani SM, Al-Kuraishy HM, Al-Gareeb AI et al (2025) The neuroprotective role of humanin in Alzheimer\u2019s disease: the molecular effects. Eur J Pharmacol. https:\/\/doi.org\/10.1016\/j.ejphar.2025.177510","journal-title":"Eur J Pharmacol"},{"key":"4055_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100163","volume":"12","author":"D Angioni","year":"2025","unstructured":"Angioni D, Middleton L, Bateman R et al (2025) Challenges and opportunities for novel combination therapies in Alzheimer\u2019s disease: a report from the EU\/US CTAD Task Force. J Prev Alzheimers Dis 12:100163. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100163","journal-title":"J Prev Alzheimers Dis"},{"key":"4055_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26062691","volume":"26","author":"SK Araj","year":"2025","unstructured":"Araj SK, Brzezik J, M\u0105dra-Gackowska K, Szeleszczuk \u0141 (2025) Overview of epitalon\u2014highly bioactive pineal tetrapeptide with promising properties. Int J Mol Sci 26:2691. https:\/\/doi.org\/10.3390\/ijms26062691","journal-title":"Int J Mol Sci"},{"key":"4055_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-025-02419-0","volume":"23","author":"M Arif","year":"2025","unstructured":"Arif M, Musleh S, Alam T (2025) DeepB3Pred: blood\u2013brain barrier peptide predictor using stacked BiGRU model with novel features. BMC Biol 23:325. https:\/\/doi.org\/10.1186\/s12915-025-02419-0","journal-title":"BMC Biol"},{"key":"4055_CR9","first-page":"179","volume":"5","author":"A Arutjunyan","year":"2012","unstructured":"Arutjunyan A, Kozina L, Stvolinskiy S et al (2012) Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. Int J Clin Exp Med 5:179\u2013185","journal-title":"Int J Clin Exp Med"},{"key":"4055_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.reth.2025.06.013","volume":"30","author":"T Asaba","year":"2025","unstructured":"Asaba T, Hamano S, Nanmo A et al (2025) Human iPSC-derived cerebral organoids reveal oxytocin-mediated protection against amyloid-\u03b2 pathology. Regen Ther 30:259\u2013267. https:\/\/doi.org\/10.1016\/j.reth.2025.06.013","journal-title":"Regen Ther"},{"key":"4055_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2024.100022","volume":"12","author":"S Aye","year":"2025","unstructured":"Aye S, Johansson G, Hock C et al (2025) Point of view: challenges in implementation of new immunotherapies for Alzheimer\u2019s disease. J Prev Alzheimers Dis 12:100022. https:\/\/doi.org\/10.1016\/j.tjpad.2024.100022","journal-title":"J Prev Alzheimers Dis"},{"key":"4055_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2018.00021","author":"MH Baig","year":"2018","unstructured":"Baig MH, Ahmad K, Rabbani G, Choi I (2018) Use of peptides for the management of Alzheimer\u2019s disease: diagnosis and inhibition. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2018.00021","journal-title":"Front Aging Neurosci"},{"key":"4055_CR13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/joim.12645","volume":"282","author":"L Bankir","year":"2017","unstructured":"Bankir L, Bichet DG, Morgenthaler NG (2017) Vasopressin: physiology, assessment and osmosensation. J Intern Med 282:284\u2013297. https:\/\/doi.org\/10.1111\/joim.12645","journal-title":"J Intern Med"},{"key":"4055_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70258","volume":"21","author":"I Barroeta","year":"2025","unstructured":"Barroeta I, Videla L, Carmona-Iragui M et al (2025) Current advances and unmet needs in Alzheimer\u2019s disease trials for individuals with Down syndrome: navigating new therapeutic frontiers. Alzheimers Dement 21:e70258. https:\/\/doi.org\/10.1002\/alz.70258","journal-title":"Alzheimers Dement"},{"key":"4055_CR15","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1124\/jpet.114.218735","volume":"351","author":"CC Benoist","year":"2014","unstructured":"Benoist CC, Kawas LH, Zhu M et al (2014) The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor\/c-Met system. J Pharmacol Exp Ther 351:390\u2013402. https:\/\/doi.org\/10.1124\/jpet.114.218735","journal-title":"J Pharmacol Exp Ther"},{"key":"4055_CR16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/0006-8993(90)90372-I","volume":"537","author":"WC Benzing","year":"1990","unstructured":"Benzing WC, Mufson EJ, Jennes L, Armstrong DM (1990) Reduction of neurotensin immunoreactivity in the amygdala in Alzheimer\u2019s disease. Brain Res 537:298\u2013302. https:\/\/doi.org\/10.1016\/0006-8993(90)90372-I","journal-title":"Brain Res"},{"key":"4055_CR17","doi-asserted-by":"publisher","unstructured":"Boules M, Li Z, Smith K, et al (2013) Diverse roles of neurotensin agonists in the central nervous system. Front Endocrinol (Lausanne) 4:. https:\/\/doi.org\/10.3389\/fendo.2013.00036","DOI":"10.3389\/fendo.2013.00036"},{"key":"4055_CR18","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/emmm.201000100","volume":"2","author":"SP Brothers","year":"2010","unstructured":"Brothers SP, Wahlestedt C (2010) Therapeutic potential of neuropeptide y (NPY) receptor ligands. EMBO Mol Med 2:429\u2013439. https:\/\/doi.org\/10.1002\/emmm.201000100","journal-title":"EMBO Mol Med"},{"key":"4055_CR19","doi-asserted-by":"crossref","unstructured":"Butterfield DA (2007) Amyloid \u03b2-peptide(1-42), oxidative stress, and Alzheimer\u2019s disease. Abeta peptide and Alzheimer\u2019s disease: celebrating a century of research. Springer London, pp 83\u201392","DOI":"10.1007\/978-1-84628-440-3_5"},{"key":"4055_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/database\/baae113","volume":"2024","author":"G Cabas-Mora","year":"2024","unstructured":"Cabas-Mora G, Daza A, Soto-Garc\u00eda N et al (2024) Peptipedia v2.0: a peptide sequence database and user-friendly web platform. A major update. Database 2024:113. https:\/\/doi.org\/10.1093\/database\/baae113","journal-title":"Database"},{"key":"4055_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrn.2018.7","volume":"19","author":"A Caron","year":"2018","unstructured":"Caron A, Lee S, Elmquist JK, Gautron L (2018) Leptin and brain-adipose crosstalks. Nat Rev Neurosci 19:153\u2013165. https:\/\/doi.org\/10.1038\/nrn.2018.7","journal-title":"Nat Rev Neurosci"},{"key":"4055_CR22","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1007\/s40120-025-00815-w","volume":"14","author":"MA Cavaco","year":"2025","unstructured":"Cavaco MA, Jang SR, Olsen C et al (2025) Global societal burden of Alzheimer\u2019s disease by severity: a targeted literature review. Neurol Ther 14:1797\u20131826. https:\/\/doi.org\/10.1007\/s40120-025-00815-w","journal-title":"Neurol Ther"},{"key":"4055_CR23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.7150\/jbm.26783","volume":"3","author":"A Chaudhary","year":"2018","unstructured":"Chaudhary A, Maurya PK, Yadav BS et al (2018) Current therapeutic targets for Alzheimer\u2019s disease. J Biomed 3:74\u201384. https:\/\/doi.org\/10.7150\/jbm.26783","journal-title":"J Biomed"},{"key":"4055_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2018.00493","volume":"11","author":"XY Chen","year":"2019","unstructured":"Chen XY, Du YF, Chen L (2019) Neuropeptides exert neuroprotective effects in Alzheimer\u2019s disease. Front Mol Neurosci 11:394000. https:\/\/doi.org\/10.3389\/fnmol.2018.00493","journal-title":"Front Mol Neurosci"},{"key":"4055_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.845747","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Zhang Q, Li B et al (2022) BBPpredict: a web service for identifying blood-brain barrier penetrating peptides. Front Genet 13:845747. https:\/\/doi.org\/10.3389\/fgene.2022.845747","journal-title":"Front Genet"},{"key":"4055_CR26","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1093\/procel\/pwac033","volume":"14","author":"Y Chen","year":"2023","unstructured":"Chen Y, Chen B, Wu T et al (2023) Cryo-EM structure of human \u03ba-opioid receptor-Gi complex bound to an endogenous agonist dynorphin A. Protein Cell 14:464\u2013468. https:\/\/doi.org\/10.1093\/procel\/pwac033","journal-title":"Protein Cell"},{"key":"4055_CR27","doi-asserted-by":"publisher","first-page":"e1534","DOI":"10.1016\/S2214-109X(24)00264-X","volume":"12","author":"S Chen","year":"2024","unstructured":"Chen S, Cao Z, Nandi A et al (2024) The global macroeconomic burden of Alzheimer\u2019s disease and other dementias: estimates and projections for 152 countries or territories. Lancet Glob Health 12:e1534\u2013e1543. https:\/\/doi.org\/10.1016\/S2214-109X(24)00264-X","journal-title":"Lancet Glob Health"},{"key":"4055_CR28","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000046219","volume":"104","author":"FS Cheng","year":"2025","unstructured":"Cheng FS, Lei JX, Zhang J et al (2025) Global burden of Alzheimer disease and other dementias reveals escalating geographical disparities and metabolic risks: a comprehensive analysis of 1990-2021 data. Medicine (Baltimore) 104:e46219. https:\/\/doi.org\/10.1097\/MD.0000000000046219","journal-title":"Medicine (Baltimore)"},{"key":"4055_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2024.150597","volume":"733","author":"P Chowdari Gurram","year":"2024","unstructured":"Chowdari Gurram P, Satarker S, Nampoothiri M (2024) Recent advances in the molecular signaling pathways of substance P in Alzheimer\u2019s disease: link to neuroinflammation associated with toll-like receptors. Biochem Biophys Res Commun 733:150597. https:\/\/doi.org\/10.1016\/j.bbrc.2024.150597","journal-title":"Biochem Biophys Res Commun"},{"key":"4055_CR30","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","volume":"19","author":"EE Congdon","year":"2023","unstructured":"Congdon EE, Ji C, Tetlow AM (2023) Tau-targeting therapies for Alzheimer disease: current status and future directions. Nat Rev Neurol 19:715\u2013736. https:\/\/doi.org\/10.1038\/s41582-023-00883-2","journal-title":"Nat Rev Neurol"},{"key":"4055_CR31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/978-3-0346-0228-0_11","volume":"102","author":"SE Counts","year":"2010","unstructured":"Counts SE, Perez SE, Ginsberg SD, Mufson EJ (2010) Neuroprotective role for galanin in Alzheimer\u2019s disease. EXS 102:143\u2013162. https:\/\/doi.org\/10.1007\/978-3-0346-0228-0_11","journal-title":"EXS"},{"key":"4055_CR32","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1007\/s00018-008-8158-3","volume":"65","author":"JN Crawley","year":"2008","unstructured":"Crawley JN (2008) Galanin impairs cognitive abilities in rodents: relevance to Alzheimer\u2019s disease. Cell Mol Life Sci 65:1836\u20131841. https:\/\/doi.org\/10.1007\/s00018-008-8158-3","journal-title":"Cell Mol Life Sci"},{"key":"4055_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70098","volume":"11","author":"JL Cummings","year":"2025","unstructured":"Cummings JL, Zhou Y, Lee G (2025) Alzheimer\u2019s disease drug development pipeline: 2025. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions 11:e70098. https:\/\/doi.org\/10.1002\/trc2.70098","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"key":"4055_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2021.786855","volume":"15","author":"DE Curley","year":"2021","unstructured":"Curley DE, Webb AE, Sheffler DJ, Haass-Koffler CL (2021) Corticotropin releasing factor binding protein as a novel target to restore brain homeostasis: lessons learned from alcohol use disorder research. Front Behav Neurosci 15:786855. https:\/\/doi.org\/10.3389\/fnbeh.2021.786855","journal-title":"Front Behav Neurosci"},{"key":"4055_CR35","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2024-335593","volume":"96","author":"R De Giorgi","year":"2025","unstructured":"De Giorgi R, Ghenciulescu A, Yotter C et al (2025) Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders. J Neurol Neurosurg Psychiatry 96:870\u2013883. https:\/\/doi.org\/10.1136\/jnnp-2024-335593","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4055_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00726-011-1184-8","volume":"45","author":"M Delgado","year":"2013","unstructured":"Delgado M, Ganea D (2013) Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids 45:25\u201339. https:\/\/doi.org\/10.1007\/s00726-011-1184-8","journal-title":"Amino Acids"},{"key":"4055_CR37","doi-asserted-by":"publisher","first-page":"D655","DOI":"10.1093\/nar\/gkj040","volume":"34","author":"F Desiere","year":"2006","unstructured":"Desiere F, Deutsch EW, King NL et al (2006) The PeptideAtlas project. Nucleic Acids Res 34:D655\u2013D658. https:\/\/doi.org\/10.1093\/nar\/gkj040","journal-title":"Nucleic Acids Res"},{"key":"4055_CR38","doi-asserted-by":"publisher","DOI":"10.1590\/1980-5764-DN-2023-0031","author":"F Duarte-Zambrano","year":"2023","unstructured":"Duarte-Zambrano F, Barrero JA, Mockus I (2023) Cerebrospinal fluid levels of hypothalamicpituitary-adrenal axis hormones in MCI and dementia due to Alzheimer\u2019s disease: a systematic review. Dement Neuropsychol. https:\/\/doi.org\/10.1590\/1980-5764-DN-2023-0031","journal-title":"Dement Neuropsychol"},{"key":"4055_CR39","doi-asserted-by":"publisher","unstructured":"Edison P, Femminella GD, Ritchie C et al (2025) Liraglutide in mild to moderate Alzheimer\u2019s disease: a phase 2b clinical trial. Nat Med (1):9. https:\/\/doi.org\/10.1038\/s41591-025-04106-7","DOI":"10.1038\/s41591-025-04106-7"},{"key":"4055_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae414","author":"B Fernandes Gomes","year":"2024","unstructured":"Fernandes Gomes B, Kumar A, Ashton NJ et al (2024) Corticotropin-releasing hormone as a candidate biomarker for parkinsonian disorders. Brain Commun. https:\/\/doi.org\/10.1093\/braincomms\/fcae414","journal-title":"Brain Commun"},{"key":"4055_CR41","doi-asserted-by":"publisher","unstructured":"Filatova E, Kasian A, Kolomin T, et al (2017) GABA, selank, and olanzapine affect the expression of genes involved in gabaergic neurotransmission in IMR-32 Cells. Front Pharmacol 8:. https:\/\/doi.org\/10.3389\/fphar.2017.00089","DOI":"10.3389\/fphar.2017.00089"},{"key":"4055_CR42","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/j.biopsych.2016.11.004","volume":"81","author":"SK Fineberg","year":"2017","unstructured":"Fineberg SK, Ross DA (2017) Oxytocin and the social brain. Biol Psychiatry 81:e19\u2013e21. https:\/\/doi.org\/10.1016\/j.biopsych.2016.11.004","journal-title":"Biol Psychiatry"},{"key":"4055_CR43","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40263-013-0076-8","volume":"27","author":"J Freiherr","year":"2013","unstructured":"Freiherr J, Hallschmid M, Frey WH et al (2013) Intranasal insulin as a treatment for Alzheimer\u2019s disease: a review of basic research and clinical evidence. CNS Drugs 27:505\u2013514. https:\/\/doi.org\/10.1007\/s40263-013-0076-8","journal-title":"CNS Drugs"},{"key":"4055_CR44","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.70175","volume":"169","author":"MA Frick","year":"2025","unstructured":"Frick MA, Woodruff JL, Caudillo YM et al (2025) Orexin\/Hypocretin modulates neuroinflammatory response to LPS in a sex and brain-region specific manner in young rats. J Neurochem 169:e70175. https:\/\/doi.org\/10.1111\/jnc.70175","journal-title":"J Neurochem"},{"key":"4055_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/biom14080926","volume":"14","author":"M Garc\u00eda-Dom\u00ednguez","year":"2024","unstructured":"Garc\u00eda-Dom\u00ednguez M (2024) Enkephalins and pain modulation: mechanisms of action and therapeutic perspectives. Biomolecules 14:926. https:\/\/doi.org\/10.3390\/biom14080926","journal-title":"Biomolecules"},{"key":"4055_CR46","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1176\/ajp.148.4.484","volume":"148","author":"DL Garver","year":"1991","unstructured":"Garver DL, Bissette G, Yao JK, Nemeroff CB (1991) Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. Am J Psychiatry 148:484\u2013488. https:\/\/doi.org\/10.1176\/ajp.148.4.484","journal-title":"Am J Psychiatry"},{"key":"4055_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2025.102563","author":"S Giri","year":"2025","unstructured":"Giri S, Chandra P (2025) Modulation of neuropathological pathways by bioactive peptides and proteins\/polypeptides: targeting oxidative stress in neurodegenerative diseases. Neuropeptides. https:\/\/doi.org\/10.1016\/j.npep.2025.102563","journal-title":"Neuropeptides"},{"key":"4055_CR48","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0149-7634(84)90022-8","volume":"8","author":"MV Graf","year":"1984","unstructured":"Graf MV, Kastin AJ (1984) Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev 8:83\u201393. https:\/\/doi.org\/10.1016\/0149-7634(84)90022-8","journal-title":"Neurosci Biobehav Rev"},{"key":"4055_CR49","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1007\/s10072-025-08456-5","volume":"46","author":"A Gupta","year":"2025","unstructured":"Gupta A, Pahal S, Kumar V, Chaudhary A (2025) Role of monoclonal antibodies in Alzheimer\u2019s disease: successes, failures, and future directions. Neurol Sci 46:5607\u20135619. https:\/\/doi.org\/10.1007\/s10072-025-08456-5","journal-title":"Neurol Sci"},{"key":"4055_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2025.102551","volume":"113","author":"PC Gurram","year":"2025","unstructured":"Gurram PC, Manandhar S, Satarker S et al (2025) Substance P mitigates lipopolysaccharide induced cognitive impairment in rats in a dose dependent manner. Neuropeptides 113:102551. https:\/\/doi.org\/10.1016\/j.npep.2025.102551","journal-title":"Neuropeptides"},{"key":"4055_CR51","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/alz.12694","volume":"19","author":"A Gustavsson","year":"2023","unstructured":"Gustavsson A, Norton N, Fast T et al (2023) Global estimates on the number of persons across the Alzheimer\u2019s disease continuum. Alzheimer\u2019s & Dementia 19:658\u2013670. https:\/\/doi.org\/10.1002\/alz.12694","journal-title":"Alzheimer's & Dementia"},{"key":"4055_CR52","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel H, Hardy J, Blennow K et al (2021) The amyloid-\u03b2 pathway in Alzheimer\u2019s disease. Mol Psychiatry 26:5481\u20135503. https:\/\/doi.org\/10.1038\/s41380-021-01249-0","journal-title":"Mol Psychiatry"},{"key":"4055_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/FDDEV.2024.1360302\/FULL","volume":"4","author":"AS Haqqani","year":"2024","unstructured":"Haqqani AS, B\u00e9langer K, Stanimirovic DB (2024) Receptor-mediated transcytosis for brain delivery of therapeutics: receptor classes and criteria. Front Drug Deliv 4:1360302. https:\/\/doi.org\/10.3389\/FDDEV.2024.1360302\/FULL","journal-title":"Front Drug Deliv"},{"key":"4055_CR54","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41589-021-00890-8","volume":"18","author":"JA Harris","year":"2022","unstructured":"Harris JA, Faust B, Gondin AB et al (2022) Selective G protein signaling driven by substance P\u2013neurokinin receptor dynamics. Nat Chem Biol 18:109\u2013115. https:\/\/doi.org\/10.1038\/s41589-021-00890-8","journal-title":"Nat Chem Biol"},{"key":"4055_CR55","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1091\/mbc.E09-02-0168","volume":"20","author":"Y Hashimoto","year":"2009","unstructured":"Hashimoto Y, Kurita M, Aiso S et al (2009) Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor \u03b1\/WSX-1\/gp130. Mol Biol Cell 20:2864\u20132873. https:\/\/doi.org\/10.1091\/mbc.E09-02-0168","journal-title":"Mol Biol Cell"},{"key":"4055_CR56","doi-asserted-by":"publisher","unstructured":"Hata S, Saito H, Kakiuchi T, et al (2023) Brain p3\u2010Alc\u03b2 peptide restores neuronal viability impaired by Alzheimer\u2019s amyloid \u03b2\u2010peptide . EMBO Mol Med 15:EMMM202217052-. https:\/\/doi.org\/10.15252\/emmm.202217052","DOI":"10.15252\/emmm.202217052"},{"key":"4055_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001714","volume":"20","author":"Y Heo","year":"2022","unstructured":"Heo Y, Ishimoto N, Jeon YE et al (2022) Structure of the human galanin receptor 2 bound to galanin and Gq reveals the basis of ligand specificity and how binding affects the G-protein interface. PLoS Biol 20:e3001714. https:\/\/doi.org\/10.1371\/journal.pbio.3001714","journal-title":"PLoS Biol"},{"key":"4055_CR58","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.01681","author":"G Hopping","year":"2014","unstructured":"Hopping G, Kellock J, Barnwal RP et al (2014) Designed \u03b1-sheet peptides inhibit amyloid formation by targeting toxic oligomers. Elife. https:\/\/doi.org\/10.7554\/eLife.01681","journal-title":"Elife"},{"key":"4055_CR59","unstructured":"Ilahi S, Beriwal N, Ilahi TB (2023) Physiology, Pineal Gland. StatPearls"},{"key":"4055_CR60","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.3390\/ijms23084259","volume":"23","author":"A Ilina","year":"2022","unstructured":"Ilina A, Khavinson V, Linkova N, Petukhov M (2022) Neuroepigenetic mechanisms of action of ultrashort peptides in Alzheimer\u2019s disease. Int J Mol Sci 23:4259. https:\/\/doi.org\/10.3390\/ijms23084259","journal-title":"Int J Mol Sci"},{"key":"4055_CR61","doi-asserted-by":"publisher","first-page":"R99","DOI":"10.1530\/EC-17-0111","volume":"6","author":"C Inda","year":"2017","unstructured":"Inda C, Armando NG, dos Santos Claro PA, Silberstein S (2017) Endocrinology and the brain: corticotropin-releasing hormone signaling. Endocr Connect 6:R99\u2013R120. https:\/\/doi.org\/10.1530\/EC-17-0111","journal-title":"Endocr Connect"},{"key":"4055_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252313086","volume":"25","author":"M J\u00e1szber\u00e9nyi","year":"2024","unstructured":"J\u00e1szber\u00e9nyi M, Thurz\u00f3 B, Jayakumar AR, Schally AV (2024) The aggravating role of failing neuropeptide networks in the development of sporadic Alzheimer\u2019s disease. Int J Mol Sci 25:13086. https:\/\/doi.org\/10.3390\/ijms252313086","journal-title":"Int J Mol Sci"},{"key":"4055_CR63","doi-asserted-by":"publisher","unstructured":"Johnson MB, Young AD, Marriott I (2017) The therapeutic potential of targeting substance P\/NK-1R interactions in inflammatory CNS disorders. Front Cell Neurosci 10:. https:\/\/doi.org\/10.3389\/fncel.2016.00296","DOI":"10.3389\/fncel.2016.00296"},{"key":"4055_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/biology12121534","volume":"12","author":"CE Karachaliou","year":"2023","unstructured":"Karachaliou CE, Livaniou E (2023) Neuroprotective action of humanin and humanin analogues: research findings and perspectives. Biol 12:1534. https:\/\/doi.org\/10.3390\/biology12121534","journal-title":"Biol"},{"key":"4055_CR65","doi-asserted-by":"publisher","first-page":"507","DOI":"10.61882\/rbmb.13.4.507","volume":"13","author":"MR Karimzadeh","year":"2025","unstructured":"Karimzadeh MR, Najmadini A, Azhdari S et al (2025) Association of Alzheimer\u2019s disease with promoter variations in NPY2R gene. Reports of Biochemistry and Molecular Biology 13:507\u2013515. https:\/\/doi.org\/10.61882\/rbmb.13.4.507","journal-title":"Reports of Biochemistry and Molecular Biology"},{"key":"4055_CR66","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1023\/A:1025493705728","volume":"135","author":"VK Khavinson","year":"2003","unstructured":"Khavinson VK, Bondarev IE, Butyugov AA (2003) Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med 135:590\u2013592. https:\/\/doi.org\/10.1023\/A:1025493705728","journal-title":"Bull Exp Biol Med"},{"key":"4055_CR67","unstructured":"Khavinson V, Evgeny G, Vladimir M, Galina R (2006) Peptide substance stimulating regeneration of central nervous system neurons, pharmaceutical composition on its base, and the method of its application"},{"key":"4055_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25030609","volume":"25","author":"V Khavinson","year":"2020","unstructured":"Khavinson V, Diomede F, Mironova E et al (2020) AEDG peptide (epitalon) stimulates gene expression and protein synthesis during neurogenesis: possible epigenetic mechanism. Molecules 25:609. https:\/\/doi.org\/10.3390\/molecules25030609","journal-title":"Molecules"},{"key":"4055_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/ph14060515","author":"V Khavinson","year":"2021","unstructured":"Khavinson V, Ilina A, Kraskovskaya N et al (2021a) Neuroprotective effects of tripeptides\u2014epigenetic regulators in mouse model of Alzheimer\u2019s disease. Pharmaceuticals. https:\/\/doi.org\/10.3390\/ph14060515","journal-title":"Pharmaceuticals"},{"key":"4055_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/MOLECULES26010159","volume":"26","author":"V Khavinson","year":"2021","unstructured":"Khavinson V, Linkova N, Kozhevnikova E, Trofimova S (2021b) EDR peptide: possible mechanism of gene expression and protein synthesis regulation involved in the pathogenesis of Alzheimer\u2019s disease. Molecules 26:159. https:\/\/doi.org\/10.3390\/MOLECULES26010159","journal-title":"Molecules"},{"key":"4055_CR71","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1093\/bioinformatics\/btr445","volume":"27","author":"Y Kim","year":"2011","unstructured":"Kim Y, Bark S, Hook V, Bandeira N (2011) NeuroPedia: neuropeptide database and spectral library. Bioinformatics 27:2772\u20132773. https:\/\/doi.org\/10.1093\/bioinformatics\/btr445","journal-title":"Bioinformatics"},{"key":"4055_CR72","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0074-7742(04)59013-X","volume":"59","author":"B Kinkead","year":"2003","unstructured":"Kinkead B, Nemeroff CB (2003) Neurotensin, schizophrenia, and antipsychotic drug action. Int Rev Neurobiol 59:327\u2013349. https:\/\/doi.org\/10.1016\/S0074-7742(04)59013-X","journal-title":"Int Rev Neurobiol"},{"key":"4055_CR73","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-025-05417-z","volume":"63","author":"U Kochman","year":"2026","unstructured":"Kochman U, Sitka H, Ku\u017aniar J et al (2026) Targeted nanoparticles for drug delivery across the blood\u2013brain barrier in early and late stages of Alzheimer\u2019s disease: a review. Mol Neurobiol 63:75. https:\/\/doi.org\/10.1007\/s12035-025-05417-z","journal-title":"Mol Neurobiol"},{"key":"4055_CR74","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s10517-019-04588-9","volume":"167","author":"LG Kolik","year":"2019","unstructured":"Kolik LG, Nadorova AV, Antipova TA et al (2019) Selank, peptide analogue of tuftsin, protects against ethanol-induced memory impairment by regulating of BDNF content in the hippocampus and prefrontal cortex in rats. Bull Exp Biol Med 167:641\u2013644. https:\/\/doi.org\/10.1007\/s10517-019-04588-9","journal-title":"Bull Exp Biol Med"},{"key":"4055_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1205207","volume":"14","author":"F Kong","year":"2023","unstructured":"Kong F, Wu T, Dai J et al (2023) Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer\u2019s disease models: a systematic review and meta-analysis of preclinical studies. Front Pharmacol 14:1205207. https:\/\/doi.org\/10.3389\/fphar.2023.1205207","journal-title":"Front Pharmacol"},{"key":"4055_CR76","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s12031-018-1226-8","volume":"68","author":"OT Korkmaz","year":"2019","unstructured":"Korkmaz OT, Ay H, Aytan N et al (2019) Vasoactive intestinal peptide decreases \u03b2-amyloid accumulation and prevents brain atrophy in the 5xFAD mouse model of Alzheimer\u2019s disease. J Mol Neurosci 68:389\u2013396. https:\/\/doi.org\/10.1007\/s12031-018-1226-8","journal-title":"J Mol Neurosci"},{"key":"4055_CR77","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1134\/S1062359018060055","volume":"45","author":"SV Koroleva","year":"2018","unstructured":"Koroleva SV, Myasoedov NF (2018) Semax as a universal drug for therapy and research. Biol Bull 45:589\u2013600. https:\/\/doi.org\/10.1134\/S1062359018060055","journal-title":"Biol Bull"},{"key":"4055_CR78","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1471-4159.2006.03693.x","volume":"97","author":"VM Kovalzon","year":"2006","unstructured":"Kovalzon VM, Strekalova TV (2006) Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem 97:303\u2013309. https:\/\/doi.org\/10.1111\/j.1471-4159.2006.03693.x","journal-title":"J Neurochem"},{"key":"4055_CR79","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1126\/science.6139875","volume":"222","author":"DT Krieger","year":"1983","unstructured":"Krieger DT (1983) Brain peptides: what, where, and why? Science 222:975\u2013985. https:\/\/doi.org\/10.1126\/science.6139875","journal-title":"Science"},{"key":"4055_CR80","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2419741121","volume":"121","author":"M Kristensen","year":"2024","unstructured":"Kristensen M (2024) Insulin-inspired peptides may open new pathways to treat Alzheimer\u2019s disease. Proc Natl Acad Sci U S A 121:e2419741121. https:\/\/doi.org\/10.1073\/pnas.2419741121","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4055_CR81","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1007\/s00429-021-02341-5","volume":"226","author":"V Kumar","year":"2021","unstructured":"Kumar V, Patiyal S, Kumar R et al (2021) B3Pdb: an archive of blood\u2013brain barrier-penetrating peptides. Brain Struct Funct 226:2489\u20132495. https:\/\/doi.org\/10.1007\/s00429-021-02341-5","journal-title":"Brain Struct Funct"},{"key":"4055_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2025.102547","volume":"113","author":"D Lanjewar","year":"2025","unstructured":"Lanjewar D, Katariya R, Kale V et al (2025) Interplay of neuropeptide Y and autophagy in Alzheimer\u2019s disease: therapeutic perspectives and mechanistic insights. Neuropeptides 113:102547. https:\/\/doi.org\/10.1016\/j.npep.2025.102547","journal-title":"Neuropeptides"},{"key":"4055_CR83","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s10517-018-4234-3","volume":"165","author":"IS Lebedeva","year":"2018","unstructured":"Lebedeva IS, Panikratova YR, Sokolov OY et al (2018) Effects of semax on the default mode network of the brain. Bull Exp Biol Med 165:653\u2013656. https:\/\/doi.org\/10.1007\/s10517-018-4234-3","journal-title":"Bull Exp Biol Med"},{"key":"4055_CR84","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.4103\/1673-5374.389364","volume":"19","author":"J Li","year":"2024","unstructured":"Li J, Huang X, An Y et al (2024) The role of snapin in regulation of brain homeostasis. Neural Regen Res 19:1696\u20131701. https:\/\/doi.org\/10.4103\/1673-5374.389364","journal-title":"Neural Regen Res"},{"key":"4055_CR85","doi-asserted-by":"publisher","DOI":"10.1111\/cns.70511","volume":"31","author":"J Li","year":"2025","unstructured":"Li J, Li Y, Wang Z et al (2025a) Oxytocin intervention mitigates pathological and behavioral impairments in APP\/PS1 mice subjected to early social isolation. CNS Neurosci Ther 31:e70511. https:\/\/doi.org\/10.1111\/cns.70511","journal-title":"CNS Neurosci Ther"},{"key":"4055_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-025-03251-4","volume":"15","author":"J Li","year":"2025","unstructured":"Li J, Lian T, Li J et al (2025b) Alzheimer\u2019s disease with depression: clinical characteristics and potential mechanisms involving orexin and brain atrophy. Transl Psychiatry 15:1\u201310. https:\/\/doi.org\/10.1038\/s41398-025-03251-4","journal-title":"Transl Psychiatry"},{"key":"4055_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2025.115328","volume":"392","author":"H Liao","year":"2025","unstructured":"Liao H, Wang X, Yang C et al (2025) Overexpression of colonic VIP ameliorates cognitive function and barrier system damage caused by sevoflurane anesthesia and surgery in aged rats with fragile brain functions. Exp Neurol 392:115328. https:\/\/doi.org\/10.1016\/j.expneurol.2025.115328","journal-title":"Exp Neurol"},{"key":"4055_CR88","doi-asserted-by":"publisher","unstructured":"Lin Z, Yu S, Yang Y, et al (2024) The double-edged effects of substance P in the pathology of Alzheimer\u2019s disease. Aging Dis 16:2870. https:\/\/doi.org\/10.14336\/ad.2024.0960","DOI":"10.14336\/ad.2024.0960"},{"key":"4055_CR89","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/jnen\/59.4.314","volume":"59","author":"RY Liu","year":"2000","unstructured":"Liu RY, Zhou JN, Hoogendijk WJG et al (2000) Decreased vasopressin gene expression in the biological clock of Alzheimer disease patients with and without depression. J Neuropathol Exp Neurol 59:314\u2013322. https:\/\/doi.org\/10.1093\/jnen\/59.4.314","journal-title":"J Neuropathol Exp Neurol"},{"key":"4055_CR90","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"JM Long","year":"2019","unstructured":"Long JM, Holtzman DM (2019) Alzheimer disease: an update on pathobiology and treatment strategies. Cell 179:312\u2013339. https:\/\/doi.org\/10.1016\/j.cell.2019.09.001","journal-title":"Cell"},{"key":"4055_CR91","doi-asserted-by":"publisher","first-page":"A6","DOI":"10.1176\/appi.neuropsych.20240253","volume":"37","author":"W L\u00f3pez-Ojeda","year":"2025","unstructured":"L\u00f3pez-Ojeda W, Hurley RA (2025) New trends in peptide therapies: perspectives and implications for clinical neurosciences. J Neuropsychiatry Clin Neurosci 37:A6-101. https:\/\/doi.org\/10.1176\/appi.neuropsych.20240253","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"4055_CR92","doi-asserted-by":"publisher","unstructured":"M. White C, Ji S, Cai H, et al (2012) Therapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders. CNS Neurol Disord - Drug Targets 9:661\u2013666. https:\/\/doi.org\/10.2174\/187152710793361595","DOI":"10.2174\/187152710793361595"},{"key":"4055_CR93","doi-asserted-by":"publisher","unstructured":"Martin LJ (2002) Peptides, hormones, and the brain and spinal cord. Encycl Hum Brain 797\u2013815. https:\/\/doi.org\/10.1016\/b0-12-227210-2\/00273-9","DOI":"10.1016\/b0-12-227210-2\/00273-9"},{"key":"4055_CR94","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/ana.410200603","volume":"20","author":"MF Mazurek","year":"1986","unstructured":"Mazurek MF, Bed MF, Bird ED, Martin JB (1986) Vasopressin in Alzheimer\u2019s disease: a study of postmortem brain concentrations. Ann Neurol 20:665\u2013670. https:\/\/doi.org\/10.1002\/ana.410200603","journal-title":"Ann Neurol"},{"key":"4055_CR95","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10571-015-0282-7","volume":"36","author":"MJ McGuire","year":"2016","unstructured":"McGuire MJ, Ishii M (2016) Leptin dysfunction and Alzheimer\u2019s disease: evidence from cellular, animal, and human studies. Cell Mol Neurobiol 36:203\u2013217. https:\/\/doi.org\/10.1007\/s10571-015-0282-7","journal-title":"Cell Mol Neurobiol"},{"key":"4055_CR96","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1523\/JNEUROSCI.0590-08.2008","volume":"28","author":"WJ Meilandt","year":"2008","unstructured":"Meilandt WJ, Yu GQ, Chin J et al (2008) Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer\u2019s disease. J Neurosci 28:5007\u20135017. https:\/\/doi.org\/10.1523\/JNEUROSCI.0590-08.2008","journal-title":"J Neurosci"},{"key":"4055_CR97","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000353848","volume":"13","author":"C M\u00e9nard","year":"2014","unstructured":"M\u00e9nard C, Herzog H, Schwarzer C, Quirion R (2014) Possible role of dynorphins in Alzheimer\u2019s disease and age-related cognitive deficits. Neurodegener Dis 13:82\u201385. https:\/\/doi.org\/10.1159\/000353848","journal-title":"Neurodegener Dis"},{"key":"4055_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.1400544","volume":"16","author":"X Meng","year":"2024","unstructured":"Meng X, Song Q, Liu Z et al (2024) Neurotoxic \u03b2-amyloid oligomers cause mitochondrial dysfunction\u2014the trigger for PANoptosis in neurons. Front Aging Neurosci 16:1400544. https:\/\/doi.org\/10.3389\/fnagi.2024.1400544","journal-title":"Front Aging Neurosci"},{"key":"4055_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118325","volume":"189","author":"NG Metzendorf","year":"2025","unstructured":"Metzendorf NG, Godec A, Petrovic A et al (2025) Somatostatin therapy, neprilysin activation, and amyloid beta reduction: a novel approach for Alzheimer\u2019s treatment. Biomed Pharmacother 189:118325. https:\/\/doi.org\/10.1016\/j.biopha.2025.118325","journal-title":"Biomed Pharmacother"},{"key":"4055_CR100","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nrn3044","volume":"12","author":"A Meyer-Lindenberg","year":"2011","unstructured":"Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M (2011) Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci 12:524\u2013538. https:\/\/doi.org\/10.1038\/nrn3044","journal-title":"Nat Rev Neurosci"},{"key":"4055_CR101","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/S00018-025-05668-Y","volume":"82","author":"R Mishra","year":"2025","unstructured":"Mishra R, Upadhyay A (2025) An update on mammalian and non-mammalian animal models for biomarker development in neurodegenerative disorders. Cell Mol Life Sci 82:147. https:\/\/doi.org\/10.1007\/S00018-025-05668-Y","journal-title":"Cell Mol Life Sci"},{"key":"4055_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.125055","volume":"669","author":"S Mojarad-Jabali","year":"2025","unstructured":"Mojarad-Jabali S, Roh KH (2025) Peptide-based inhibitors and nanoparticles: emerging therapeutics for Alzheimer\u2019s disease. Int J Pharm 669:125055. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.125055","journal-title":"Int J Pharm"},{"key":"4055_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118332","author":"I Moreno-Madrid","year":"2025","unstructured":"Moreno-Madrid I, Romero-Imbroda J, Reyes-Bueno JA et al (2025) Peripheral expression of NPY1R-based heteroreceptor complexes reflects hippocampal neuroimmune status: novel biomarkers for early Alzheimer\u2019s disease detection. Biomed Pharmacother. https:\/\/doi.org\/10.1016\/j.biopha.2025.118332","journal-title":"Biomed Pharmacother"},{"key":"4055_CR104","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1405423","volume":"15","author":"CE Muolokwu","year":"2024","unstructured":"Muolokwu CE, Chaulagain B, Gothwal A et al (2024) Functionalized nanoparticles to deliver nucleic acids to the brain for the treatment of Alzheimer\u2019s disease. Front Pharmacol 15:1405423. https:\/\/doi.org\/10.3389\/fphar.2024.1405423","journal-title":"Front Pharmacol"},{"key":"4055_CR105","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3233\/JAD-2010-1221","volume":"19","author":"MP Murphy","year":"2010","unstructured":"Murphy MP, Levine H (2010) Alzheimer\u2019s disease and the amyloid-\u03b2 peptide. J Alzheimers Dis 19:311\u2013323. https:\/\/doi.org\/10.3233\/JAD-2010-1221","journal-title":"J Alzheimers Dis"},{"key":"4055_CR106","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.neuroscience.2022.02.014","volume":"497","author":"CA Netto","year":"2022","unstructured":"Netto CA (2022) Role of brain \u0392-endorphin in memory modulation revisited. Neuroscience 497:30\u201338. https:\/\/doi.org\/10.1016\/j.neuroscience.2022.02.014","journal-title":"Neuroscience"},{"key":"4055_CR107","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1021\/acs.jpcb.2c01769","volume":"126","author":"HL Nguyen","year":"2022","unstructured":"Nguyen HL, Linh HQ, Krupa P et al (2022) Amyloid \u03b2 dodecamer disrupts the neuronal membrane more strongly than the mature fibril: understanding the role of oligomers in neurotoxicity. J Phys Chem B 126:3659\u20133672. https:\/\/doi.org\/10.1021\/acs.jpcb.2c01769","journal-title":"J Phys Chem B"},{"key":"4055_CR108","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41380-022-01792-4","volume":"28","author":"J Nowell","year":"2023","unstructured":"Nowell J, Blunt E, Edison P (2023a) Incretin and insulin signaling as novel therapeutic targets for Alzheimer\u2019s and Parkinson\u2019s disease. Mol Psychiatry 28:217\u2013229. https:\/\/doi.org\/10.1038\/s41380-022-01792-4","journal-title":"Mol Psychiatry"},{"key":"4055_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023b.101979","volume":"89","author":"J Nowell","year":"2023","unstructured":"Nowell J, Blunt E, Gupta D, Edison P (2023b) Antidiabetic agents as a novel treatment for Alzheimer\u2019s and Parkinson\u2019s disease. Ageing Res Rev 89:101979. https:\/\/doi.org\/10.1016\/j.arr.2023b.101979","journal-title":"Ageing Res Rev"},{"key":"4055_CR110","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1017\/s0033291700033675","volume":"26","author":"JT O\u2019Brien","year":"1996","unstructured":"O\u2019Brien JT, Ames D, Schweitzer I et al (1996) Enhanced adrenal sensitivity to adrenocorticotrophic hormone (ACTH) is evidence of HPA axis hyperactivity in Alzheimer\u2019s disease. Psychol Med 26:7\u201314. https:\/\/doi.org\/10.1017\/s0033291700033675","journal-title":"Psychol Med"},{"key":"4055_CR111","doi-asserted-by":"publisher","first-page":"11852","DOI":"10.1073\/pnas.1510117112","volume":"112","author":"C O\u2019Connor","year":"2015","unstructured":"O\u2019Connor C, White KL, Doncescu N et al (2015) NMR structure and dynamics of the agonist dynorphin peptide bound to the human kappa opioid receptor. Proc Natl Acad Sci U S A 112:11852\u201311857. https:\/\/doi.org\/10.1073\/pnas.1510117112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4055_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2019.00043","volume":"11","author":"S Ouanes","year":"2019","unstructured":"Ouanes S, Popp J (2019) High cortisol and the risk of dementia and Alzheimer\u2019s disease: a review of the literature. Front Aging Neurosci 11:435469. https:\/\/doi.org\/10.3389\/fnagi.2019.00043","journal-title":"Front Aging Neurosci"},{"key":"4055_CR113","doi-asserted-by":"publisher","unstructured":"Pahal S, Pahal V, Chaudhary A (2025) From data to discovery: neuroinformatics in understanding Alzheimer\u2019s disease. J Biosci 50:. https:\/\/doi.org\/10.1007\/s12038-024-00486-z","DOI":"10.1007\/s12038-024-00486-z"},{"key":"4055_CR114","doi-asserted-by":"publisher","DOI":"10.1155\/bn\/9627699","volume":"2025","author":"R Pang","year":"2025","unstructured":"Pang R, Jia Q, Ma C et al (2025) Alzheimer\u2019s disease: the current and emerging treatment approaches. Behav Neurol 2025:9627699. https:\/\/doi.org\/10.1155\/bn\/9627699","journal-title":"Behav Neurol"},{"key":"4055_CR115","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2217864120","volume":"120","author":"PC Pao","year":"2023","unstructured":"Pao PC, Seo J, Lee A et al (2023) A Cdk5-derived peptide inhibits Cdk5\/p25 activity and improves neurodegenerative phenotypes. Proc Natl Acad Sci USA 120:e2217864120. https:\/\/doi.org\/10.1073\/pnas.2217864120","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4055_CR116","doi-asserted-by":"publisher","DOI":"10.2210\/PDB7VGX\/PDB","author":"C Park","year":"2022","unstructured":"Park C, Kim J, Jeong H et al (2022a) Neuropeptide Y Y1 receptor (NPY1R) in complex with G protein and its endogeneous peptide-agonist neuropeptide Y (NPY). Worldw Protein Data Bank. https:\/\/doi.org\/10.2210\/PDB7VGX\/PDB","journal-title":"Worldw Protein Data Bank"},{"key":"4055_CR117","doi-asserted-by":"publisher","unstructured":"Park C, Kim J, Ko SB, et al (2022b) Structural basis of neuropeptide Y signaling through Y1 receptor. Nat Commun 13:. https:\/\/doi.org\/10.1038\/s41467-022-28510-6","DOI":"10.1038\/s41467-022-28510-6"},{"key":"4055_CR118","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1006\/nbdi.2001.0395","volume":"8","author":"WA Pedersen","year":"2001","unstructured":"Pedersen WA, McCullers D, Culmsee C et al (2001) Corticotropin-releasing hormone protects neurons against insults relevant to the pathogenesis of Alzheimer\u2019s disease. Neurobiol Dis 8:492\u2013503. https:\/\/doi.org\/10.1006\/nbdi.2001.0395","journal-title":"Neurobiol Dis"},{"key":"4055_CR119","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s000180300029","volume":"60","author":"T Pedrazzini","year":"2003","unstructured":"Pedrazzini T, Pralong F, Grouzmann E (2003) Neuropeptide Y: the universal soldier. Cell Mol Life Sci 60:350\u2013377. https:\/\/doi.org\/10.1007\/s000180300029","journal-title":"Cell Mol Life Sci"},{"key":"4055_CR120","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/msj.20157","volume":"77","author":"DP Perl","year":"2010","unstructured":"Perl DP (2010) Neuropathology of Alzheimer\u2019s disease. Mt Sinai J Med 77:32\u201342. https:\/\/doi.org\/10.1002\/msj.20157","journal-title":"Mt Sinai J Med"},{"key":"4055_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22010338","volume":"22","author":"A Pilozzi","year":"2021","unstructured":"Pilozzi A, Carro C, Huang X (2021) Roles of \u03b2-endorphin in stress, behavior, neuroinflammation, and brain energy metabolism. Int J Mol Sci 22:1\u201325. https:\/\/doi.org\/10.3390\/ijms22010338","journal-title":"Int J Mol Sci"},{"key":"4055_CR122","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.neurobiolaging.2019.01.002","volume":"76","author":"A Plagman","year":"2019","unstructured":"Plagman A, Hoscheidt S, McLimans KE et al (2019) Cholecystokinin and Alzheimer\u2019s disease: a biomarker of metabolic function, neural integrity, and cognitive performance. Neurobiol Aging 76:201\u2013207. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2019.01.002","journal-title":"Neurobiol Aging"},{"key":"4055_CR123","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/EJA.0b013e32831c8644","volume":"26","author":"CJD Pomfrett","year":"2009","unstructured":"Pomfrett CJD, Dolling S, Anders NRK et al (2009) Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia. Eur J Anaesthesiol 26:128\u2013134. https:\/\/doi.org\/10.1097\/EJA.0b013e32831c8644","journal-title":"Eur J Anaesthesiol"},{"key":"4055_CR124","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1021\/acs.molpharmaceut.4c01327","volume":"22","author":"R Prades","year":"2025","unstructured":"Prades R, Teixid\u00f3 M, Oller-Salvia B (2025) New trends in brain shuttle peptides. Mol Pharm 22:1100\u20131109. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c01327","journal-title":"Mol Pharm"},{"key":"4055_CR125","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2025.1608401","volume":"16","author":"M Puig","year":"2025","unstructured":"Puig M, Shubow S (2025) Immunogenicity of therapeutic peptide products: bridging the gaps regarding the role of product-related risk factors. Front Immunol 16:1608401. https:\/\/doi.org\/10.3389\/FIMMU.2025.1608401","journal-title":"Front Immunol"},{"key":"4055_CR126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/database\/baab055","volume":"2021","author":"C Quiroz","year":"2021","unstructured":"Quiroz C, Saavedra YB, Armijo-Galdames B et al (2021) Peptipedia: a user-friendly web application and a comprehensive database for peptide research supported by machine learning approach. Database 2021:1\u20139. https:\/\/doi.org\/10.1093\/database\/baab055","journal-title":"Database"},{"key":"4055_CR127","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1084\/JEM.20182042","volume":"215","author":"RM Ransohoff","year":"2018","unstructured":"Ransohoff RM (2018) All (animal) models (of neurodegeneration) are wrong. Are they also useful? J Exp Med 215:2955. https:\/\/doi.org\/10.1084\/JEM.20182042","journal-title":"J Exp Med"},{"key":"4055_CR128","doi-asserted-by":"publisher","unstructured":"Reich N, H\u00f6lscher C (2024) Cholecystokinin (CCK): a neuromodulator with therapeutic potential in Alzheimer\u2019s and Parkinson\u2019s disease. Front Neuroendocrinol 73:\u00a0https:\/\/doi.org\/10.1016\/j.yfrne.2024.101122","DOI":"10.1016\/j.yfrne.2024.101122"},{"key":"4055_CR129","doi-asserted-by":"publisher","first-page":"6552","DOI":"10.1523\/JNEUROSCI.5173-06.2007","volume":"27","author":"RA Rissman","year":"2007","unstructured":"Rissman RA, Lee KF, Vale W, Sawchenko PE (2007) Corticotropin-releasing factor receptors differentially regulate stress-induced tau phosphorylation. J Neurosci 27:6552\u20136562. https:\/\/doi.org\/10.1523\/JNEUROSCI.5173-06.2007","journal-title":"J Neurosci"},{"key":"4055_CR130","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/head.13084","volume":"57","author":"AF Russo","year":"2017","unstructured":"Russo AF (2017) Overview of neuropeptides: awakening the senses? Headache 57:37\u201346. https:\/\/doi.org\/10.1111\/head.13084","journal-title":"Headache"},{"key":"4055_CR131","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nrn2092","volume":"8","author":"T Sakurai","year":"2007","unstructured":"Sakurai T (2007) The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci 8:171\u2013181. https:\/\/doi.org\/10.1038\/nrn2092","journal-title":"Nat Rev Neurosci"},{"key":"4055_CR132","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1124\/pharmrev.124.001117","volume":"76","author":"KE Sandoval","year":"2024","unstructured":"Sandoval KE, Witt KA (2024) Somatostatin: linking cognition and Alzheimer disease to therapeutic targeting. Pharmacol Rev 76:1291\u20131325. https:\/\/doi.org\/10.1124\/pharmrev.124.001117","journal-title":"Pharmacol Rev"},{"key":"4055_CR133","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/BF01971753","volume":"37","author":"D Schneider-Helmert","year":"1981","unstructured":"Schneider-Helmert D, Schoenenberger GA (1981) The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia 37:913\u2013917. https:\/\/doi.org\/10.1007\/BF01971753","journal-title":"Experientia"},{"key":"4055_CR134","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1021\/acschemneuro.1c00707","volume":"13","author":"MFM Sciacca","year":"2022","unstructured":"Sciacca MFM, Naletova I, Giuffrida ML, Attanasio F (2022) Semax, a synthetic regulatory peptide, affects copper-induced abeta aggregation and amyloid formation in artificial membrane models. ACS Chem Neurosci 13:486\u2013496. https:\/\/doi.org\/10.1021\/acschemneuro.1c00707","journal-title":"ACS Chem Neurosci"},{"key":"4055_CR135","doi-asserted-by":"publisher","unstructured":"Seo J, Pao P-C, Kritskiy O, et al (2020) A cyclin-dependent kinase 5-derived peptide inhibits Cdk5\/p25 activity and improves neurodegenerative phenotypes. bioRxiv 2020.05.12.090472. https:\/\/doi.org\/10.1101\/2020.05.12.090472","DOI":"10.1101\/2020.05.12.090472"},{"key":"4055_CR136","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2025.1518868","volume":"18","author":"A Shaikh","year":"2025","unstructured":"Shaikh A, Ahmad F, Teoh SL et al (2025) Neurotrophic factor alpha 1 gene therapy in Alzheimer\u2019s disease: scope and advancements. Front Mol Neurosci 18:1518868. https:\/\/doi.org\/10.3389\/fnmol.2025.1518868","journal-title":"Front Mol Neurosci"},{"key":"4055_CR137","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.3390\/neurolint16060100","volume":"16","author":"K Shapovalova","year":"2024","unstructured":"Shapovalova K, Zorkina Y, Abramova O et al (2024) The role of neuropeptide Y in the pathogenesis of Alzheimer\u2019s disease: diagnostic significance and neuroprotective functions. Neurol Int 16:1318\u20131331. https:\/\/doi.org\/10.3390\/neurolint16060100","journal-title":"Neurol Int"},{"key":"4055_CR138","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1039\/d4md00630e","volume":"16","author":"A Sharma","year":"2024","unstructured":"Sharma A, Rudrawar S, Bharate SB, Jadhav HR (2024) Recent advancements in the therapeutic approaches for Alzheimer\u2019s disease treatment: current and future perspective. RSC Med Chem 16:652\u2013693. https:\/\/doi.org\/10.1039\/d4md00630e","journal-title":"RSC Med Chem"},{"key":"4055_CR139","doi-asserted-by":"publisher","DOI":"10.3390\/cells14191506","volume":"14","author":"X Shen","year":"2025","unstructured":"Shen X, Li H, Zhang B et al (2025) Tau-targeted therapeutic strategies: mechanistic targets, clinical pipelines, and analysis of failures. Cells 14:1506. https:\/\/doi.org\/10.3390\/cells14191506","journal-title":"Cells"},{"key":"4055_CR140","doi-asserted-by":"publisher","first-page":"S188","DOI":"10.37765\/ajmc.2022.89236","volume":"28","author":"AP Skaria","year":"2022","unstructured":"Skaria AP (2022) The economic and societal burden of Alzheimer disease: managed care considerations. Am J Manag Care 28:S188\u2013S196. https:\/\/doi.org\/10.37765\/ajmc.2022.89236","journal-title":"Am J Manag Care"},{"key":"4055_CR141","doi-asserted-by":"publisher","first-page":"383","DOI":"10.31887\/dcns.2006.8.4\/ssmith","volume":"8","author":"SM Smith","year":"2006","unstructured":"Smith SM, Vale WW (2006) The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues Clin Neurosci 8:383\u2013395. https:\/\/doi.org\/10.31887\/dcns.2006.8.4\/ssmith","journal-title":"Dialogues Clin Neurosci"},{"key":"4055_CR142","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1126\/science.6157191","volume":"209","author":"SH Snyder","year":"1980","unstructured":"Snyder SH (1980) Brain peptides as neurotransmitters. Science 209:976. https:\/\/doi.org\/10.1126\/science.6157191","journal-title":"Science"},{"key":"4055_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19336896.2017.1405207","volume":"12","author":"M Solarski","year":"2018","unstructured":"Solarski M, Wang H, Wille H, Schmitt-Ulms G (2018) Somatostatin in Alzheimer\u2019s disease: a new role for an old player. Prion 12:1\u20138. https:\/\/doi.org\/10.1080\/19336896.2017.1405207","journal-title":"Prion"},{"key":"4055_CR144","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029790","volume":"7","author":"M Song","year":"2012","unstructured":"Song M, Xiong J, Wang Y et al (2012) VIP enhances phagocytosis of fibrillar beta-amyloid by microglia and attenuates amyloid deposition in the brain of APP\/PS1 mice. PLoS One 7:e29790. https:\/\/doi.org\/10.1371\/journal.pone.0029790","journal-title":"PLoS One"},{"key":"4055_CR145","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70448","volume":"21","author":"L Sordo","year":"2025","unstructured":"Sordo L, Du A, Sandadi V et al (2025) Leptin levels are associated with body mass index and Alzheimer\u2019s disease in Down syndrome. Alzheimers Dement 21:e70448. https:\/\/doi.org\/10.1002\/alz.70448","journal-title":"Alzheimers Dement"},{"key":"4055_CR146","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1749-6632.1987.tb24964.x","volume":"512","author":"EBD Souza","year":"1987","unstructured":"Souza EBD, Whitehouse PJ, Price DL, Vale WW (1987) Abnormalities in corticotropin-releasing hormone (CRH) in Alzheimer\u2019s disease and other human disorders. Ann N Y Acad Sci 512:237\u2013247. https:\/\/doi.org\/10.1111\/j.1749-6632.1987.tb24964.x","journal-title":"Ann N Y Acad Sci"},{"key":"4055_CR147","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1212\/wnl.35.7.1057","volume":"35","author":"R Sulkava","year":"1985","unstructured":"Sulkava R, Erkinjuntti T, Laatikainen T (1985) CSF \u03b2-endorphin and \u03b2-lipotropin in Alzheimer\u2019s disease and multi-infarct dementia. Neurology 35:1057\u20131058. https:\/\/doi.org\/10.1212\/wnl.35.7.1057","journal-title":"Neurology"},{"key":"4055_CR148","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2015.00221","volume":"6","author":"X Sun","year":"2015","unstructured":"Sun X, Chen WD, Wang YD (2015) \u03b2-Amyloid: the key peptide in the pathogenesis of Alzheimer\u2019s disease. Front Pharmacol 6:221. https:\/\/doi.org\/10.3389\/FPHAR.2015.00221","journal-title":"Front Pharmacol"},{"key":"4055_CR149","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11111487","author":"X Sun","year":"2021","unstructured":"Sun X, Deng Y, Fu X et al (2021) Angiv-analog dihexa rescues cognitive impairment and recovers memory in the app\/ps1 mouse via the pi3k\/akt signaling pathway. Brain Sci. https:\/\/doi.org\/10.3390\/brainsci11111487","journal-title":"Brain Sci"},{"key":"4055_CR150","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202409392","author":"Y Sun","year":"2025","unstructured":"Sun Y, Andrikopoulos N, Zhang G et al (2025) Formation of a \u03b2-endorphin corona mitigates Alzheimer\u2019s amyloidogenesis. Small. https:\/\/doi.org\/10.1002\/smll.202409392","journal-title":"Small"},{"key":"4055_CR151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vhri.2023.09.008","volume":"40","author":"LX Tay","year":"2024","unstructured":"Tay LX, Ong SC, Tay LJ et al (2024) Economic burden of Alzheimer\u2019s disease: a systematic review. Value in Health Regional Issues 40:1\u201312. https:\/\/doi.org\/10.1016\/j.vhri.2023.09.008","journal-title":"Value in Health Regional Issues"},{"key":"4055_CR152","doi-asserted-by":"publisher","DOI":"10.1002\/alz.089273","volume":"20","author":"H Tayran","year":"2024","unstructured":"Tayran H, Yilmaz E, Bhattarai P et al (2024a) ABCA7\u2010dependent neuropeptide\u2010Y signalling is a resilience mechanism required for synaptic integrity in Alzheimer\u2019s disease. Alzheimers Dement 20:e089273. https:\/\/doi.org\/10.1002\/alz.089273","journal-title":"Alzheimers Dement"},{"key":"4055_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2024.100642","volume":"4","author":"H Tayran","year":"2024","unstructured":"Tayran H, Yilmaz E, Bhattarai P et al (2024b) ABCA7-dependent induction of neuropeptide Y is required for synaptic resilience in Alzheimer\u2019s disease through BDNF\/NGFR signaling. Cell Genom 4:100642. https:\/\/doi.org\/10.1016\/j.xgen.2024.100642","journal-title":"Cell Genom"},{"key":"4055_CR154","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/00000542-200609000-00026","volume":"105","author":"TA Treschan","year":"2006","unstructured":"Treschan TA, Peters J (2006) The vasopressin system: physiology and clinical strategies. Anesthesiology 105:599\u2013612. https:\/\/doi.org\/10.1097\/00000542-200609000-00026","journal-title":"Anesthesiology"},{"key":"4055_CR155","doi-asserted-by":"publisher","first-page":"616","DOI":"10.30773\/pi.2020.0136","volume":"17","author":"YH Um","year":"2020","unstructured":"Um YH, Lim HK (2020) Orexin and Alzheimer\u2019s disease: a new perspective. Psychiatry Investig 17:616\u2013626. https:\/\/doi.org\/10.30773\/pi.2020.0136","journal-title":"Psychiatry Investig"},{"key":"4055_CR156","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00429-011-0375-0","volume":"217","author":"S Van Dorpe","year":"2012","unstructured":"Van Dorpe S, Bronselaer A, Nielandt J et al (2012) Brainpeps: the blood-brain barrier peptide database. Brain Struct Funct 217:687\u2013718. https:\/\/doi.org\/10.1007\/s00429-011-0375-0","journal-title":"Brain Struct Funct"},{"key":"4055_CR157","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-019-0581-8","volume":"9","author":"D Vandael","year":"2019","unstructured":"Vandael D, Gounko NV (2019) Corticotropin releasing factor-binding protein (CRF-BP) as a potential new therapeutic target in Alzheimer\u2019s disease and stress disorders. Transl Psychiatry 9:1\u201311. https:\/\/doi.org\/10.1038\/s41398-019-0581-8","journal-title":"Transl Psychiatry"},{"key":"4055_CR158","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.5599\/ADMET.2988","volume":"13","author":"R Vargas","year":"2025","unstructured":"Vargas R, Martinez-Martinez N, Lizano-Barrantes C et al (2025) Advancing through the blood-brain barrier: mechanisms, challenges and drug delivery strategies: review paper. ADMET DMPK 13:2988\u20132988. https:\/\/doi.org\/10.5599\/ADMET.2988","journal-title":"ADMET DMPK"},{"key":"4055_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2025.102559","volume":"114","author":"P Verma","year":"2025","unstructured":"Verma P, Khatun R, Jew KA et al (2025) Therapeutic potential of small peptides in Alzheimer\u2019s disease: advances in memory restoration and targeted delivery systems. Neuropeptides 114:102559. https:\/\/doi.org\/10.1016\/j.npep.2025.102559","journal-title":"Neuropeptides"},{"key":"4055_CR160","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/S0165-6147(99)01357-7","volume":"20","author":"JP Vincent","year":"1999","unstructured":"Vincent JP, Mazella J, Kitabgi P (1999) Neurotensin and neurotensin receptors. Trends Pharmacol Sci 20:302\u2013309. https:\/\/doi.org\/10.1016\/S0165-6147(99)01357-7","journal-title":"Trends Pharmacol Sci"},{"key":"4055_CR161","doi-asserted-by":"publisher","unstructured":"Volkova A, Shadrina M, Kolomin T, et al (2016) Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol 7:. https:\/\/doi.org\/10.3389\/fphar.2016.00031","DOI":"10.3389\/fphar.2016.00031"},{"key":"4055_CR162","doi-asserted-by":"publisher","DOI":"10.1093\/database\/bav038","volume":"2015","author":"Y Wang","year":"2015","unstructured":"Wang Y, Wang M, Yin S et al (2015) NeuroPep: a comprehensive resource of neuropeptides. Database 2015:. https:\/\/doi.org\/10.1093\/database\/bav038","journal-title":"Database"},{"key":"4055_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2023.168416","volume":"436","author":"M Wang","year":"2024","unstructured":"Wang M, Wang L, Xu W et al (2024) NeuroPep 2.0: an updated database dedicated to neuropeptide and its receptor annotations. J Mol Biol 436:. https:\/\/doi.org\/10.1016\/j.jmb.2023.168416","journal-title":"J Mol Biol"},{"key":"4055_CR164","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2012.00146","volume":"3","author":"KEB Webling","year":"2012","unstructured":"Webling KEB, Runesson J, Bartfai T, Langel \u00dc (2012) Galanin receptors and ligands. Front Endocrinol (Lausanne) 3:34916. https:\/\/doi.org\/10.3389\/fendo.2012.00146","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"4055_CR165","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55381-w","volume":"15","author":"TL Williams","year":"2024","unstructured":"Williams TL, Verdon G, Kuc RE et al (2024) Structural and functional determination of peptide versus small molecule ligand binding at the apelin receptor. Nat Commun 15(1):10714-. https:\/\/doi.org\/10.1038\/s41467-024-55381-w","journal-title":"Nat Commun"},{"key":"4055_CR166","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1007\/s13346-024-01558-1","volume":"14","author":"CYJ Wong","year":"2024","unstructured":"Wong CYJ, Baldelli A, Hoyos CM et al (2024) Insulin delivery to the brain via the nasal route: unraveling the potential for Alzheimer\u2019s disease therapy. Drug Deliv Transl Res 14:1776\u20131793. https:\/\/doi.org\/10.1007\/s13346-024-01558-1","journal-title":"Drug Deliv Transl Res"},{"key":"4055_CR167","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/JCMA.0000000000001252","volume":"88","author":"CK Wu","year":"2025","unstructured":"Wu CK, Fuh JL (2025) A 2025 update on treatment strategies for the Alzheimer\u2019s disease spectrum. J Chin Med Assoc 88:495\u2013502. https:\/\/doi.org\/10.1097\/JCMA.0000000000001252","journal-title":"J Chin Med Assoc"},{"key":"4055_CR168","doi-asserted-by":"publisher","first-page":"7027","DOI":"10.1523\/JNEUROSCI.0408-14.2014","volume":"34","author":"Z Xiao","year":"2014","unstructured":"Xiao Z, Cilz NI, Kurada L et al (2014) Activation of neurotensin receptor 1 facilitates neuronal excitability and spatial learning and memory in the entorhinal cortex: beneficial actions in an Alzheimer\u2019s disease model. J Neurosci 34:7027\u20137042. https:\/\/doi.org\/10.1523\/JNEUROSCI.0408-14.2014","journal-title":"J Neurosci"},{"key":"4055_CR169","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02107-5","volume":"10","author":"W Xiao","year":"2025","unstructured":"Xiao W, Jiang W, Chen Z et al (2025) Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines. Signal Transduct Target Ther 10:74. https:\/\/doi.org\/10.1038\/s41392-024-02107-5","journal-title":"Signal Transduct Target Ther"},{"key":"4055_CR170","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1585711","volume":"13","author":"Z Xiaopeng","year":"2025","unstructured":"Xiaopeng Z, Jing Y, Xia L et al (2025) Global burden of Alzheimer\u2019s disease and other dementias in adults aged 65 years and older, 1991\u20132021: population-based study. Front Public Health 13:1585711. https:\/\/doi.org\/10.3389\/fpubh.2025.1585711","journal-title":"Front Public Health"},{"key":"4055_CR171","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3390\/PHARMACEUTICS17081041","volume":"17","author":"HM Yang","year":"2025","unstructured":"Yang HM (2025) Overcoming the blood\u2013brain barrier: advanced strategies in targeted drug delivery for neurodegenerative diseases. Pharmaceutics 17:1041. https:\/\/doi.org\/10.3390\/PHARMACEUTICS17081041","journal-title":"Pharmaceutics"},{"key":"4055_CR172","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.4103\/NRR.NRR-D-24-00934","volume":"20","author":"E Yang","year":"2025","unstructured":"Yang E, Abd-Elrahman KS (2025) Alzheimer\u2019s disease treatment landscape: current therapies and emerging mechanism-targeted approaches. Neural Regen Res 20:3531\u20133532. https:\/\/doi.org\/10.4103\/NRR.NRR-D-24-00934","journal-title":"Neural Regen Res"},{"key":"4055_CR173","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2025.101018","author":"F Yasuno","year":"2025","unstructured":"Yasuno F, Nakagome K, Omachi Y et al (2025) Leptin and inflammatory pathways in the Alzheimer\u2019s disease continuum: implications for glial activation and neuropsychiatric symptoms. Brain, Behavior, & Immunity - Health. https:\/\/doi.org\/10.1016\/j.bbih.2025.101018","journal-title":"Brain, Behavior, & Immunity - Health"},{"key":"4055_CR174","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-32616-7","volume":"8","author":"K Yen","year":"2018","unstructured":"Yen K, Wan J, Mehta HH et al (2018) Humanin prevents age-related cognitive decline in mice and is associated with improved cognitive age in humans. Sci Rep 8:1\u201310. https:\/\/doi.org\/10.1038\/s41598-018-32616-7","journal-title":"Sci Rep"},{"key":"4055_CR175","doi-asserted-by":"publisher","unstructured":"Zagon IS, Mclaughlin PJ (2017) Endogenous opioids in the etiology and treatment of multiple sclerosis. Mult Scler Perspect Treat Pathog 125\u2013138. https:\/\/doi.org\/10.15586\/codon.multiplesclerosis.2017.ch8","DOI":"10.15586\/codon.multiplesclerosis.2017.ch8"},{"key":"4055_CR176","doi-asserted-by":"publisher","first-page":"10048","DOI":"10.1021\/acs.jafc.9b03793","volume":"67","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Yang X, Wang S, Song S (2019) Ginsenoside Rg3 prevents cognitive impairment by improving mitochondrial dysfunction in the rat model of Alzheimer\u2019s disease. J Agric Food Chem 67:10048\u201310058. https:\/\/doi.org\/10.1021\/acs.jafc.9b03793","journal-title":"J Agric Food Chem"},{"key":"4055_CR177","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01911-3","volume":"9","author":"J Zhang","year":"2024","unstructured":"Zhang J, Zhang Y, Wang J et al (2024) Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther 9:211. https:\/\/doi.org\/10.1038\/s41392-024-01911-3","journal-title":"Signal Transduct Target Ther"},{"key":"4055_CR178","doi-asserted-by":"publisher","DOI":"10.3389\/fddev.2025.1644633","volume":"5","author":"X Zhang","year":"2025","unstructured":"Zhang X, Fu M, Wang Y, Wu T (2025) Strategies for delivering drugs across the blood-brain barrier for the treatment of neurodegenerative diseases. Front Drug Deliv 5:1644633. https:\/\/doi.org\/10.3389\/fddev.2025.1644633","journal-title":"Front Drug Deliv"},{"key":"4055_CR179","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1019943","volume":"13","author":"S Zhu","year":"2022","unstructured":"Zhu S, Hu X, Bennett S et al (2022) Galanin family peptides: molecular structure, expression and roles in the neuroendocrine axis and in the spinal cord. Front Endocrinol (Lausanne) 13:1019943. https:\/\/doi.org\/10.3389\/fendo.2022.1019943","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Cell and Tissue Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00441-026-04055-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00441-026-04055-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00441-026-04055-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T02:14:30Z","timestamp":1774923270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00441-026-04055-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":179,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4055"],"URL":"https:\/\/doi.org\/10.1007\/s00441-026-04055-8","relation":{},"ISSN":["0302-766X","1432-0878"],"issn-type":[{"value":"0302-766X","type":"print"},{"value":"1432-0878","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}